康艾注射液配合化疗治疗晚期大肠癌患者的临床效果  

Analysis of the Effects of Kangai Injection Combined with Chemotherapy on Advanced Colorectal Cancer

作　　者：乔运余 QIAO Yun-Yu(Colorectal Surgery,Shenyang Anorectal Hospital,Shenyang 110054,China)

机构地区：[1]沈阳市肛肠医院大肠外科,沈阳110054

出　　处：《中国药物经济学》2022年第2期50-53,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨康艾注射液配合化疗治疗晚期大肠癌患者的临床效果。方法选取2019年4月至2020年4月于沈阳市肛肠医院就诊的80例晚期大肠癌患者作为研究对象,随机分为对照组与观察组,各40例。对照组采用化疗药物治疗,观察组采用康艾注射液配合化疗治疗,比较两组的治疗效果。结果观察组治疗有效率为72.5%,高于对照组的45.0%,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组(P<0.05);观察组1年、3年生存率高于对照组(P<0.05);治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+) 高于对照组,CD8^(+)低于对照组,差异有统计学意义(P<0.05)。结论针对晚期大肠癌患者在接受化疗治疗的基础上联合康艾注射液治疗可获得更加满意的疗效,不良反应低。Objective To explore the effect of Kangai Injection combined with chemotherapy on advanced colorectal cancer.Methods From April 2019 to April 2020, a total of 80 patients with advanced colorectal cancer treated in Shenyang Anorectal Hospital were admitted as the research object and were randomly divided into 2 groups, with 40 cases in each group. The control group was treated with chemotherapy, and the observation group was treated with Kangai Injection combined with chemotherapy.Compare the treatment effects of the 2 groups. Results The effective rate of 45.0% in the control group was lower than 72.5% in the observation group, which was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, which was statistically significant(P<0.05). The 1-year and 3-year survival rates of the observation group were higher than those of the control group(P<0.05). after treatment, CD3^(+), CD4^(+), CD4^(+)/CD8^(+)in the observation group were higher than those in the control group, and CD8^(+) in the observation group was lower than the control group.,there was a statistical difference in the data(P<0.05). Conclusion For patients with advanced colorectal cancer, combined with Kangai Injection on the basis of chemotherapy treatment can obtain a more satisfactory curative effect with low adverse reactions,which is worthy of clinical promotion and application.

关 键 词：康艾注射液 化疗 晚期 大肠癌 效果 

分 类 号：R735.3[医药卫生—肿瘤] R289.5[医药卫生—临床医学]